Updated efficacy and safety results from the phase 2 study of serplulimab, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors
机构：[1]Shanghai East Hosp, Shanghai, Peoples R China[2]Eastern Theater Gen Hosp PLA China, Qinhuai Med Area, Nanjing, Peoples R China[3]Zhejiang Canc Hosp, Hangzhou, Peoples R China浙江省肿瘤医院[4]Affiliated Canc Hosp, Guangzhou, Peoples R China[5]Inst Guangzhou Med Univ, Guangzhou, Peoples R China[6]Taizhou First Peoples Hosp, Taizhou, Peoples R China[7]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China华中科技大学同济医学院附属同济医院[8]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China[9]Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China[10]Cent South Univ, Xiangya Hosp 3, Changsha, Peoples R China[11]Zhongshan City Peoples Hosp, Zhongshan, Peoples R China[12]Hebei Med Univ, Dept Med Oncol, Hosp 4, Shijiazhuang, Peoples R China临床科室肿瘤内科河北医科大学第四医院[13]Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China重庆医科大学附属第一医院[14]Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China[15]Guangdong Pharmaceut Univ, Affiliated Hosp 1, Sch Clin Med, Guangzhou, Peoples R China[16]First Peoples Hosp Foshan, Foshan, Peoples R China[17]Shanghai Henlius Biotech Inc, Shanghai, Peoples R China
第一作者机构：[1]Shanghai East Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Jin Li,Qin Shukui,Zhong Haijun,et al.Updated efficacy and safety results from the phase 2 study of serplulimab, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):doi:10.1200/JCO.2022.40.16_suppl.2592.
APA：
Jin Li,Qin, Shukui,Zhong, Haijun,Chuan Jin,Chen, Lili...&Jun Zhu.(2022).Updated efficacy and safety results from the phase 2 study of serplulimab, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Jin Li,et al."Updated efficacy and safety results from the phase 2 study of serplulimab, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022)
医学